Breast cancer is characterized by molecular heterogeneity, and four major
breast cancer subtypes have been identified, each characterized by significant differences in survival, prognosis, and response to
therapy. We have studied the effects of
docetaxel treatment on apoptosis and
survivin expression in four
breast cancer cell lines: MCF7 (
luminal A:
estrogen receptor-positive and
progesterone receptor-positive, ErbB2-negative), BT474 (
luminal B:
estrogen receptor/
progesterone receptor/ErbB2-positive), SKBR3 (HER2-like:
estrogen receptor/
progesterone receptor-negative, ErbB2-positive), and MDA-MB231 (basal-like:
estrogen receptor/
progesterone receptor/ErbB2-negative). We demonstrated that
docetaxel-induced apoptosis and
survivin upregulation (MCF7 p = 0.002, BT474 p = 0.001, SKBR3 p = 0.001) in
luminal A/B and HER2-like cells, while it induced mainly
necrosis and a lower rate of
survivin upregulation (MDA-MB231 p = 0.035) in basal-like cells.
Wortmannin, a p-Akt inhibitor, was able to revert surviving upregulation and, at the same time, induced an increase of
docetaxel-dependent apoptosis, suggesting that reduced levels of
survivin can sensitize
tumor cells to apoptosis. These data show that the analyzed
breast cancer cell lines respond differently to
docetaxel, depending on their receptor expression profile and molecular phenotype. Yet, these data confirm that one of the pathways involved in
taxane-related chemoresistance is the upregulation of
survivin. Further studies on the molecular mechanisms of chemoresistance and on the different modalities of apoptosis induced by chemotherapeutic agents are requested to better understand how
cancer cells evade cell death, in order to design new kind of
anticancer agents and
survivin could represent a future target for this kind of research.